Evidence map›Paper›PMID 38841789›Full record

Trial reportHaematologica2024

Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.

Shinya Rai, Won Seog Kim, Kiyoshi Ando, Ilseung Choi, Koji Izutsu, Norifumi Tsukamoto, Dai Maruyama, Kunihiro Tsukasaki, Junya Kuroda, Jun Ando and 22 more

Abstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Shinya RaiDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka-Sayama. rai@med.kindai.ac.jp.
Won Seog KimDivision of Hematology Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul.
Kiyoshi AndoHematology and Oncology, Tokai University Hospital, Isehara.
Ilseung ChoiHematology, National Hospital Organization Kyushu Cancer Center, Fukuoka.
Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, Tokyo.
Norifumi TsukamotoOncology Center, Gunma University Hospital, Maebashi.
Dai MaruyamaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo.
Kunihiro TsukasakiHematology, International Medical Center, Saitama Medical University, Saitama.
Junya KurodaHematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto.
Jun AndoDepartment of Hematology, Juntendo University School of Medicine, Tokyo.
Michihiro HidakaHematology, National Hospital Organization Kumamoto Medical Center, Kumamoto.
Youngil KohInternal Medicine, Seoul National University Hospital, Seoul.
Hisashi KatoHematology and Oncology, Osaka University Graduate School of Medicine, Suita.
Toshiki UchidaHematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya.
Deok Hwan YangHematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National Medical School, Gwangju.
Kenji IshitsukaHematology and Rheumatology, Kagoshima University Hospital, Kagoshima.
Kenichi IshizawaThird Internal Medicine, Yamagata University Hospital, Yamagata.
Jin Seok KimDivision of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul.
Hong Ghi LeeHematology and Oncology, Konkuk University Medical Center, Seoul.
Hironobu MinamiMedical Oncology/Hematology, Kobe University Hospital, Kobe.
Hyeon Seok EomCenter for Hematologic Malignancy, National Cancer Center, Goyang-si.
Mitsutoshi KurosawaHematology, National Hospital Organization Hokkaido Cancer Center, Sapporo.
Jae Hoon LeeDivision of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon.
Jong Seok LeeDivision of Hematology-Oncology, Seoul National University Bundang Hospital, Gyeonggi.
Won Sik LeeInternal Medicine, Inje University Busan Paik Hospital, Busan.
Hirokazu NagaiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya.
Takero ShindoHematology and Oncology, Kyoto University Hospital, Kyoto.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul.
Shinichiro YoshidaHematology, National Hospital Organization Nagasaki Medical Center, Omura.
Mireille GillingsHUYABIO International, San Diego, CA.
Hiroshi OnogiHuya Japan GK, Tokyo.
Kensei TobinaiDepartment of Hematology, National Cancer Center Hospital, Tokyo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, T-Cell, PeripheralAdultAgedDrug Resistance, NeoplasmFemaleHistone Deacetylase InhibitorsHumansMaleMiddle AgedNeoplasm Recurrence, LocalRecurrenceTreatment OutcomeHistone Deacetylase Inhibitors

Identifiers

PMID38841789
PMCPMC11443361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.